PURPOSE: To reduce accumulation in the abdomen by MORF/cMORF pretargeting, 111In was compared to 99mTc as the radiolabel. PROCEDURES: After receiving either 99mTc (MAG3)-cMORF or 111In (DTPA)-cMORF, normal mice were imaged and killed for pharmacokinetics. Thereafter, tumored mice were pretargeted withMORF-antibody, 48 h later were given an injection of 99mTc- or 111In-cMORF, and finally were imaged repeatedly. RESULTS: The cMORF biodistribution in both normal and pretargeted tumored mice was influenced by its radiolabel. While excretion of both 99mTc-cMORF and 111In-cMORF was rapid and mainly through the kidneys, about 2% of 99mTc accumulated in the intestines compared toessentially no intestinal accumulation for 111In at any time. Tumor accumulation was unchanged. CONCLUSION: In applications of MORF/cMORF pretargeting intended to image organs deep within the abdomen such as the pancreas, radiolabeling with 111In may be superior to 99mTc.
PURPOSE: To reduce accumulation in the abdomen by MORF/cMORF pretargeting, 111In was compared to 99mTc as the radiolabel. PROCEDURES: After receiving either 99mTc (MAG3)-cMORF or 111In (DTPA)-cMORF, normal mice were imaged and killed for pharmacokinetics. Thereafter, tumoredmice were pretargeted withMORF-antibody, 48 h later were given an injection of 99mTc- or 111In-cMORF, and finally were imaged repeatedly. RESULTS: The cMORF biodistribution in both normal and pretargeted tumoredmice was influenced by its radiolabel. While excretion of both 99mTc-cMORF and 111In-cMORF was rapid and mainly through the kidneys, about 2% of 99mTc accumulated in the intestines compared toessentially no intestinal accumulation for 111In at any time. Tumor accumulation was unchanged. CONCLUSION: In applications of MORF/cMORF pretargeting intended to image organs deep within the abdomen such as the pancreas, radiolabeling with 111In may be superior to 99mTc.
Authors: P Magnani; G Paganelli; G Modorati; F Zito; C Songini; F Sudati; P Koch; H R Maecke; R Brancato; A G Siccardi; F Fazio Journal: J Nucl Med Date: 1996-06 Impact factor: 10.057
Authors: Robert M Sharkey; Thomas M Cardillo; Edmund A Rossi; Chien-Hsing Chang; Habibe Karacay; William J McBride; Hans J Hansen; Ivan D Horak; David M Goldenberg Journal: Nat Med Date: 2005-10-30 Impact factor: 53.440
Authors: Habibe Karacay; Pierre-Yves Brard; Robert M Sharkey; Chien-Hsing Chang; Edmund A Rossi; William J McBride; Dan R Ragland; Ivan D Horak; David M Goldenberg Journal: Clin Cancer Res Date: 2005-11-01 Impact factor: 12.531
Authors: Guozheng Liu; Shuping Dou; Ali Akalin; Mary Rusckowski; Philip R Streeter; Leonard D Shultz; Dale L Greiner Journal: Nucl Med Biol Date: 2012-02-10 Impact factor: 2.408
Authors: Guozheng Liu; Shuping Dou; Dengfeng Cheng; Jean Leif; Mary Rusckowski; Philip R Streeter; Leonard D Shultz; Donald J Hnatowich; Dale L Greiner Journal: Mol Pharm Date: 2011-04-21 Impact factor: 4.939
Authors: Shuping Dou; Yuzhen Wang; Bruce Barton; Ling Chen; Mary Rusckowski; Leonard D Shultz; Dale L Greiner; Guozheng Liu Journal: Nucl Med Biol Date: 2013-10-09 Impact factor: 2.408